While distinct reports indicate an increase in incidence rates of selected cancers [110,111,112], other studies argue against an association of tumor incidence and CD26/DPP4 inhibition and some analyses even indicate that CD26/DPP4 inhibition might instead improve outcomes related to certain tumor types [113,114,115,116,117,118]. This evidence concerns the gene DPP4 and cancer.